{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:14:54Z","timestamp":1772856894393,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11886-019-1229-2","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T08:03:27Z","timestamp":1574928207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of Pulmonary Arterial Hypertension in the Pediatric Patient"],"prefix":"10.1007","volume":"21","author":[{"given":"Jordan E.","family":"Ezekian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"4","key":"1229_CR1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/hrt.2008.150086","volume":"95","author":"SG Haworth","year":"2009","unstructured":"Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart. 2009;95(4):312\u20137.","journal-title":"Heart."},{"issue":"16","key":"1229_CR2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/CIRCULATIONAHA.110.969584","volume":"124","author":"RL van Loon","year":"2011","unstructured":"van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755\u201364.","journal-title":"Circulation."},{"issue":"1","key":"1229_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.amjcard.2010.02.023","volume":"106","author":"RL van Loon","year":"2010","unstructured":"van Loon RL, Roofthooft MT, Delhaas T, van Osch-Gevers M, ten Harkel AD, Strengers JL, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol. 2010;106(1):117\u201324.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1229_CR4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCULATIONAHA.111.026591","volume":"125","author":"RJ Barst","year":"2012","unstructured":"Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension. Circulation. 2012;125(1):113\u201322.","journal-title":"Circulation."},{"issue":"2","key":"1229_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164\u201372.","journal-title":"Circulation."},{"issue":"19","key":"1229_CR6","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.113.005698","volume":"129","author":"RJ Barst","year":"2014","unstructured":"Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914\u201323.","journal-title":"Circulation."},{"issue":"25 Suppl","key":"1229_CR7","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1229_CR8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1183\/13993003.01177-2015","volume":"46","author":"EM Lau","year":"2015","unstructured":"Lau EM, Tamura Y, McGoon MD, Sitbon O. The 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J. 2015;46(4):879\u201382.","journal-title":"Eur Respir J"},{"issue":"21","key":"1229_CR9","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","volume":"132","author":"SH Abman","year":"2015","unstructured":"\u2022\u2022 Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037\u201399 These represent the first consensus guidelines specifically focused on diagnosis and management of pediatric pulmonary hypertension from the American Heart Association and American Thoracic Society.","journal-title":"Circulation"},{"issue":"25 Suppl","key":"1229_CR10","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1229_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ppul.20051","volume":"38","author":"EB Rosenzweig","year":"2004","unstructured":"Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol. 2004;38(1):2\u201322.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"1229_CR12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/2045-8932.83445","volume":"1","author":"AE Lammers","year":"2011","unstructured":"Lammers AE, Adatia I, Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, et al. Functional classification of pulmonary hypertension in children: report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ. 2011;1(2):280\u20135.","journal-title":"Pulm Circ"},{"key":"1229_CR13","unstructured":"E Hatano, T. Strasser. Primary pulmonary hypertension: report on a WHO meeting, Geneva, 15\u201317 October, 1973. Geneva: World Health Organization; 1975. 1975."},{"key":"1229_CR14","unstructured":"S Rich, LJ Rubin, Abenhail L Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6\u201310, 1998). . 1998."},{"issue":"12 Suppl S","key":"1229_CR15","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","volume":"43","author":"G Simonneau","year":"2004","unstructured":"Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S\u201312S.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1229_CR16","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):S43\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl","key":"1229_CR17","doi-asserted-by":"crossref","first-page":"D117","DOI":"10.1016\/j.jacc.2013.10.028","volume":"62","author":"DD Ivy","year":"2013","unstructured":"Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D117\u201326.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1229_CR18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/687764","volume":"6","author":"WM Zijlstra","year":"2016","unstructured":"\u2022\u2022 Zijlstra WM, Douwes JM, Ploegstra MJ, Krishnan U, Roofthooft MT, Hillege HL, et al. Clinical classification in pediatric pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ. 2016;6(3):302\u201312 Findings from this study suggest that the NICE CHD classification is applicable to patients with specific groups of CHD but highlights limitations of the classification system as some patients are unable to be classified based on the current criteria.","journal-title":"Pulm Circ"},{"issue":"2","key":"1229_CR19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/2045-8932.83456","volume":"1","author":"MJ Cerro","year":"2011","unstructured":"Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286\u201398.","journal-title":"Pulm Circ"},{"issue":"1","key":"1229_CR20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S1047951107001849","volume":"18","author":"ME van Albada","year":"2008","unstructured":"van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease--the need for refinement of the Evian-Venice classification. Cardiol Young. 2008;18(1):10\u20137.","journal-title":"Cardiol Young"},{"key":"1229_CR21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jpeds.2009.02.036","volume":"155","author":"RLE van Loon","year":"2009","unstructured":"van Loon RLE, Roofthooft MTR, van Osch-Gevers M, Delhaas T, Strengers JLM, Blom NA, et al. Clinical characterization of pediatric pulmonary hypertension- complex presentation and diagnosis. J Pediatr. 2009;155:176\u201382.","journal-title":"J Pediatr"},{"issue":"1","key":"1229_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1017\/S1047951107001850","volume":"18","author":"I Schulze-Neick","year":"2008","unstructured":"Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart--cleaning up a dog\u2019s dinner. Cardiol Young. 2008;18(1):22\u20135.","journal-title":"Cardiol Young"},{"issue":"2","key":"1229_CR23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCOUTCOMES.108.787176","volume":"1","author":"SK Pasquali","year":"2008","unstructured":"Pasquali SK, Hall M, Slonim AD, Jenkins KJ, Marino BS, Cohen MS, et al. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes. 2008;1(2):74\u201383.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1229_CR24","doi-asserted-by":"crossref","unstructured":"Antosova M, Mokra D, Pepucha L, Plevkova J, Buday T, Sterusky M, et al. Physiology of nitric oxide in the respiratory system. Physiol Res 2017;66 (Suppl. 2):S159-SS72.","DOI":"10.33549\/physiolres.933673"},{"issue":"6","key":"1229_CR25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201304-0686PP","volume":"188","author":"JR Klinger","year":"2013","unstructured":"Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(6):639\u201346.","journal-title":"Am J Respir Crit Care Med"},{"key":"1229_CR26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM200002173420704","volume":"342","author":"RH Clark","year":"2000","unstructured":"Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342:469\u201374.","journal-title":"N Engl J Med"},{"issue":"2","key":"1229_CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/2045-8932.97589","volume":"2","author":"RJ Barst","year":"2012","unstructured":"Barst RJ, Channick R, Ivy D, Goldstein B. Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Pulm Circ. 2012;2(2):139\u201347.","journal-title":"Pulm Circ"},{"issue":"3","key":"1229_CR28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0735-1097(98)00668-8","volume":"33","author":"AM Atz","year":"1999","unstructured":"Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol. 1999;33(3):813\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1229_CR29","first-page":"257","volume":"2014","author":"G Butrous","year":"2014","unstructured":"Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract. 2014;2014(3):257\u201390.","journal-title":"Glob Cardiol Sci Pract"},{"key":"1229_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","volume":"172","author":"J Wharton","year":"2005","unstructured":"Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1229_CR31","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00246-009-9523-1","volume":"30","author":"AJ Huddleston","year":"2009","unstructured":"Huddleston AJ, Knoderer CA, Morris JL, Ebenroth ES. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol. 2009;30(7):871\u201382.","journal-title":"Pediatr Cardiol"},{"issue":"6","key":"1229_CR32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PCC.0b013e31828aa5ee","volume":"14","author":"KD Hill","year":"2013","unstructured":"Hill KD, Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, et al. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med. 2013;14(6):593\u2013600.","journal-title":"Pediatr Crit Care Med"},{"issue":"13","key":"1229_CR33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/eurheartj\/ehn215","volume":"29","author":"A Giardini","year":"2008","unstructured":"Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29(13):1681\u20137.","journal-title":"Eur Heart J"},{"issue":"1","key":"1229_CR34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00246-015-1238-x","volume":"37","author":"MR Sabri","year":"2016","unstructured":"Sabri MR, Zolfi-Gol A, Ahmadi A, Haghjooy-Javanmard S. Effect of tadalafil on myocardial and endothelial function and exercise performance after modified Fontan operation. Pediatr Cardiol. 2016;37(1):55\u201361.","journal-title":"Pediatr Cardiol"},{"issue":"11","key":"1229_CR35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.110.981746","volume":"123","author":"DJ Goldberg","year":"2011","unstructured":"Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123(11):1185\u201393.","journal-title":"Circulation."},{"issue":"9","key":"1229_CR36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004571","volume":"11","author":"AM Garcia","year":"2018","unstructured":"Garcia AM, Nakano SJ, Karimpour-Fard A, Nunley K, Blain-Nelson P, Stafford NM, et al. Phosphodiesterase-5 is elevated in failing single ventricle myocardium and affects cardiomyocyte remodeling in vitro. Circ Heart Fail. 2018;11(9):e004571.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"1229_CR37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","volume":"125","author":"RJ Barst","year":"2012","unstructured":"Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324\u201334.","journal-title":"Circulation."},{"issue":"6","key":"1229_CR38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1164\/rccm.201210-1928PP","volume":"187","author":"SH Abman","year":"2013","unstructured":"Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, et al. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med. 2013;187(6):572\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1229_CR39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-010-2065-4","volume":"37","author":"A Fraisse","year":"2011","unstructured":"Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011;37(3):502\u20139.","journal-title":"Intensive Care Med"},{"issue":"4","key":"1229_CR40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ppul.23935","volume":"53","author":"F Kipfmueller","year":"2018","unstructured":"Kipfmueller F, Schroeder L, Berg C, Heindel K, Bartmann P, Mueller A. Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia. Pediatr Pulmonol. 2018;53(4):452\u201360.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"1229_CR41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ppul.23503","volume":"52","author":"LK Darland","year":"2017","unstructured":"Darland LK, Dinh KL, Kim S, Placencia JL, Varghese NP, Ruiz F, et al. Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. Pediatr Pulmonol. 2017;52(2):232\u20137.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"1229_CR42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2125.2005.02553.x","volume":"61","author":"ST Forgue","year":"2006","unstructured":"Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1229_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2018.03.015","volume":"201","author":"DJ Goldberg","year":"2018","unstructured":"Goldberg DJ, Zak V, Goldstein BH, McCrindle BW, Menon SC, Schumacher KR, et al. Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. Am Heart J. 2018;201:1\u20138.","journal-title":"Am Heart J"},{"key":"1229_CR44","first-page":"215","volume":"53","author":"GJ Muirhead","year":"2002","unstructured":"Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol. 2002;53:215\u2013305.","journal-title":"Br J Clin Pharmacol"},{"issue":"9147","key":"1229_CR45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(98)09423-9","volume":"353","author":"A Benigni","year":"1999","unstructured":"Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353(9147):133\u20138.","journal-title":"Lancet"},{"issue":"9288","key":"1229_CR46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358(9288):1119\u201323.","journal-title":"Lancet"},{"issue":"23","key":"1229_CR47","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Galie","year":"2008","unstructured":"Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139.","journal-title":"Circulation."},{"issue":"9","key":"1229_CR48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318.","journal-title":"N Engl J Med"},{"key":"1229_CR49","unstructured":"A study to assess whether macitentan delays disease progression in children with pulmonary arterial hypertension (PAH) (TOMORROW) 2017 [NCT02932410]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02932410."},{"key":"1229_CR50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, WAea L. A comparison of continuous intravenouse epoprostenol (prostacyclin) with conventional therapy for pulmonary hypertension. N Engl J Med. 1996;334:296\u2013301.","journal-title":"N Engl J Med"},{"key":"1229_CR51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","volume":"121","author":"RJ Barst","year":"1994","unstructured":"Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409\u201315.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1229_CR52","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/hrt.2006.096412","volume":"93","author":"AE Lammers","year":"2007","unstructured":"Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart. 2007;93(6):739\u201343.","journal-title":"Heart."},{"issue":"3","key":"1229_CR53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijcard.2007.08.084","volume":"129","author":"A Limsuwan","year":"2008","unstructured":"Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol. 2008;129(3):333\u20138.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1229_CR54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2007.09.031","volume":"51","author":"DD Ivy","year":"2008","unstructured":"Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(2):161\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1229_CR55","doi-asserted-by":"crossref","first-page":"e13106","DOI":"10.1111\/petr.13106","volume":"22","author":"L\u00e1szl\u00f3 Ablonczy","year":"2017","unstructured":"Ablonczy L, Tordas D, Kis E, Szatmari A. Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension-bridge-to-transplant or long-term treatment? Pediatr Transplant. 2018;22(2).","journal-title":"Pediatric Transplantation"},{"key":"1229_CR56","doi-asserted-by":"crossref","first-page":"175346661876649","DOI":"10.1177\/1753466618766490","volume":"12","author":"JC Coons","year":"2018","unstructured":". Coons JC, Miller T. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience. Ther Adv Respir Dis. 2018;12:1753466618766490 This review reports the evidence for and use of treprostinil, the first oral prostacyclin approved for treatment of PAH.","journal-title":"Ther Adv Respir Dis"},{"key":"1229_CR57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpeds.2018.04.052","volume":"200","author":"KM Lawrence","year":"2018","unstructured":"Lawrence KM, Hedrick HL, Monk HM, Herkert L, Waqar LN, Hanna BD, et al. Treprostinil improves persistent pulmonary hypertension associated with congenital diaphragmatic hernia. J Pediatr. 2018;200:44\u20139.","journal-title":"J Pediatr"},{"key":"1229_CR58","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/00005344-200306000-00012","volume":"41","author":"M Wade","year":"2003","unstructured":"Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol. 2003;41:908\u201315.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"1229_CR59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1229-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:46:07Z","timestamp":1606437967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1229-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1229-2","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"28 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jordan E. Ezekian declares no conflict of interest.Kevin D. Hill reports another from Actelion (he is a site PI for a multicenter trial of macitentan for treatment of PAH in children).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"162"}}